A phase 1, open-label, dose-escalation study of SGN-CD19B in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Seattle Genetics

Protocol Number
SGN19B-001

To Learn More Call
(201)-510-0950